



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.e-jmii.com



Perspectives

Ticagrelor: A promising role in preventing multi-organ failure among patients with sepsis due to resistant gram-positive cocci



Shio-Shin Jean ^{a,b}, Shun-Chung Hsueh ^c, Juey-Jen Hwang ^{d,e},
Po-Ren Hsueh ^{f,g,*}

^a Department of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

^b Department of Emergency Medicine, Department of Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medicine University, Taipei, Taiwan

^c Department of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

^d Cardiovascular Center, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan

^e Cardiovascular Division, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan

^f Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

^g Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Received 13 June 2019; received in revised form 16 June 2019; accepted 20 June 2019

Available online 26 June 2019

KEYWORDS

Ticagrelor;
Clopidogrel;
Anti-platelet agent;
P2Y₁₂;
Gram-positive cocci

* Corresponding author. Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan.
E-mail address: hsporen@ntu.edu.tw (P.-R. Hsueh).

Despite recent advances in optimal antibiotic choice and intensive care support, substantial case-fatality rates are frequently encountered among patients with severe sepsis.^{1–6} Infections and septicemia – with a complex dysregulated mechanism that is as yet poorly understood – are usually associated with activation of platelets, a subsequent platelet-leukocyte heterotypic aggregation,

ultimately causing multi-organ failure.^{2,6} Of particular note is the receptor P2Y₁₂ on platelets, which was shown to play a pivotal role in amplifying the release of pro-inflammatory chemokines from the granules within platelets, perpetuating the inflammatory response related to tumor necrosis factor- α and interleukin-6, and causing platelet-mediated inflammation.^{2,7,8} By contrast, adenosine has an inhibitory effect on responses of platelets as well as broad effects on some pathways involved in innate immunity. Consequently, adenosine was considered to exert a protective effect against pulmonary injury in murine experiment models.⁹ Based on the aforementioned theories, as seen in one retrospective investigation evaluating the incidence and severity of community-acquired pneumonia (CAP) among heterogeneous CAP patients,¹⁰ the anti-platelet agent characteristic of antagonizing the function of the P2Y₁₂ receptor (while assisting the retention of adenosine within cells) favorably prevents sepsis-related organ dysfunction and reduces case-fatality rates.

Ticagrelor, an effective agent that reversibly inhibits P2Y₁₂ receptor and adenosine transport ENT1 (type 1 equilibrative nucleoside transporter), was approved in 2011 for the prevention of severe cardiovascular events among patients with significant coronary ischemia or stroke.^{2,11} With a single ticagrelor dose ranging from 45 to 90 mg, a dose-proportional increased inhibition of platelet aggregation was demonstrated.¹¹ Compared with the other P2Y₁₂ receptor antagonist clopidogrel (irreversibly and non-competitively binds to the P2Y₁₂ receptor, but has no known effect on adenosine metabolism), ticagrelor showed significantly greater efficacy in inhibiting platelet aggregation.¹² Unsurprisingly, it also showed greater clinical efficacy in reducing rates of mortality due to vascular causes (myocardial infarction, cerebrovascular accident, etc.), without significantly increasing the rates of overall major bleeding events (NCT00391872).¹¹

Apart from reports on the prominent anti-platelet effect of ticagrelor, a post hoc analysis in the PLATO (Platelet Inhibition and Patient Outcomes) trial demonstrated reduced rates of mortality-owing to events of pneumonia or worsening pulmonary function-in patients who received ticagrelor therapy when compared to those in patients who received clopidogrel.⁷ In addition, with respect to the in vitro efficacy of ticagrelor against bacteria, Lancellotti et al. observed that ticagrelor and its major metabolites (M5 AR-C133913, M7, M8 AR-C124910) possessed in vitro activities against many important antibiotic-resistant gram-positive cocci (GPC).¹² In that study, the minimal bactericidal concentration (MBC) against methicillin-resistant (MR) *Staphylococcus aureus* (MRSA) and glycopeptide-intermediate *S. aureus* was 20 $\mu\text{g}/\text{mL}$, whereas MBC of 30 $\mu\text{g}/\text{mL}$ against MR-*Staphylococcus epidermidis*, as well as of 40 $\mu\text{g}/\text{mL}$ against *Enterococcus faecalis* and *Streptococcus agalactiae*, were noted.¹² Moreover, ticagrelor was able to increase the bactericidal activity of rifampicin, ciprofloxacin, and vancomycin in a disc diffusion assay.¹³ The bactericidal activity of ticagrelor was similar to that of daptomycin against MRSA in a time-killing curve study.¹² Furthermore, a sub-minimal bactericidal concentration of ticagrelor (10 $\mu\text{g}/\text{mL}$) in combination with vancomycin (4 $\mu\text{g}/\text{mL}$) killed approximately 50% of the initial MRSA inoculum.¹² The latter result fully demonstrated a

synergistic activity between ticagrelor and vancomycin against MRSA strains.

Lancellotti et al. demonstrated that in a mouse model, the conventional oral antiplatelet dosages of ticagrelor (3 mg/kg loading dose, then 1.5 mg/kg twice daily) inhibited biofilm growth on *S. aureus* pre-infected implants and dissemination of bacteria to surrounding tissues.¹³ However, the in vivo antibacterial activity of ticagrelor antiplatelet dosages was observed in mouse; the ticagrelor pharmacokinetics might be different in humans.¹²

Regarding the pharmacokinetics of ticagrelor (with a >99.8% plasma protein-bound percentage), its median time to peak concentration and half-life is 2–3 h and 6.7–9.1 h, respectively, after multiple twice-daily dosing.¹³ The main excretion of ticagrelor is 58% through feces, and 27% through kidneys.¹³ Li et al. reported that in Chinese patients, the maximal concentration in serum on day 1 and day 7 after 90 mg ticagrelor administration twice daily (following 90 mg administration on day 1) was only 0.82 $\mu\text{g}/\text{mL}$ and 1.27 $\mu\text{g}/\text{mL}$, respectively.¹⁴ Hiasa et al. also demonstrated that for Asian patients, the maximal concentration in serum on day 1 and day 28, after 90 mg ticagrelor administration twice daily for stable coronary arterial disease, was only 0.61 $\mu\text{g}/\text{mL}$ and 0.93 $\mu\text{g}/\text{mL}$, respectively, in Japanese patients (n = 33); and 0.76 $\mu\text{g}/\text{mL}$ and 1.38 $\mu\text{g}/\text{mL}$, respectively, in non-Japanese patients (n = 7).¹⁵ To address the great discrepancy between MBC and low serum concentration in patients, Lancellotti et al. proposed that the antibacterial activity of ticagrelor at infection sites may still be achieved through local, possibly platelet-driven, drug accumulation.¹²

Although ticagrelor is possibly in vitro active against drug-resistant GPC, as also reported by Lancellotti et al., it was in vitro ineffective against gram-negative bacteria (*Escherichia coli* ATCC 8739, and *Pseudomonas aeruginosa* PAK laboratory strain), even at concentrations up to 80 $\mu\text{g}/\text{mL}$.¹² However, Rahman et al. demonstrated that at a dose of 100 mg/kg in mice, ticagrelor could reduce pulmonary neutrophil recruitment and attenuate lung injury severity to a considerable degree in a murine model with abdominal sepsis (induced by cecal ligation and puncture for tested mice).¹⁶

In conclusion, through inhibition of the P2Y₁₂ receptor in conjunction with enhancement of adenosine reuptake, ticagrelor strongly inhibits platelet aggregation and further platelet-leukocyte heterotypic aggregation that are universally catastrophic to organ function in sepsis patients. This drug might have a promising role in reducing the severity of lung injury caused by GPC sepsis. The optimal dose of ticagrelor as a supplementary option to decrease the severity of multi-organ failure (including lung damage) among patients with significant GPC infections, however, remains to be investigated. Furthermore, in vitro susceptibility studies on the action of ticagrelor against clinically important resistant GPC isolates (particularly vancomycin-resistant *E. faecium*) obtained from different geographical areas, and in vivo studies comparing the incidence of colonization/infection due to GPC among patients receiving ticagrelor and other anti-platelet agents, are necessary. Further investigations on attenuation of organ failure severity by ticagrelor addition for patients with severe septicemia may be warranted.

Conflicts of interest

All authors have no conflicts of interest to declare.

References

1. Angus DC, van der Poll T. Severe sepsis and septic shock. *N Engl J Med* 2013;**369**:840–51.
2. Sexton TR, Zhang G, Macaulay TE, Callahan LA, Charnigo R, Vsevolozhskaya OA, et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. *JACC Basic Transl Sci* 2018;**3**:435–49.
3. Garcia-Obregon S, Azkargorta M, Seijas I, Pilar-Orive J, Borrego F, Elortza F, et al. Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. *J Microbiol Immunol Infect* 2018;**51**:465–72.
4. Chang TH, Wu ET, Lu CY, Huang SC, Yang TI, Wang CC, et al. Pathogens and outcomes in pediatric septic shock patients supported by extracorporeal membrane oxygenation. *J Microbiol Immunol Infect* 2018;**51**:385–91.
5. Lee MS, Tseng YH, Chen YC, Kuo CH, Wang SL, Lin MH, et al. M2 macrophage subset decrement is an indicator of bleeding tendency in pediatric dengue disease. *J Microbiol Immunol Infect* 2018;**51**:829–38.
6. Chang K, Lee NY, Ko WC, Lin WR, Chen YH, Tsai JJ, et al. Characteristics of scrub typhus, murine typhus, and Q fever among elderly patients: prolonged prothrombin time as a predictor for severity. *J Microbiol Immunol Infect* 2019;**52**: 54–61.
7. Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. *Platelets* 2014;**25**:517–25.
8. Evans DJ, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, et al. Platelet P2Y₁₂ receptor influences the vessel wall response to arterial injury and thrombosis. *Circulation* 2009;**119**:116–22.
9. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. *Nat Rev Drug Discov* 2006;**5**:247–64.
10. Gross AK, Dunn SP, Feola DJ, Martin CA, Charnigo R, Li Z, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. *J Thromb Thrombolysis* 2013;**35**:147–54.
11. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;**361**:1045–57.
12. Lancellotti P, Musumeci L, Jacques N, Servais L, Goffin E, Pirotte B, et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant Gram-positive bacteria. *JAMA Cardiol* 2019 May 8. <https://doi.org/10.1001/jamacardio.2019.1189> [Epub ahead of print].
13. Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. *Pharmacotherapy* 2014;**34**:1077–90.
14. Li H, Guo J, Carlson GF, Teng R. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. *Br J Clin Pharmacol* 2016;**82**: 352–61.
15. Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. *Cardiovasc Interv Ther* 2014;**29**:324–33.
16. Rahman M, Gustafsson D, Wang Y, Thorlacius H, Braun OÖ. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. *Platelets* 2014;**25**:257–63.